The Claim
In patients with atherosclerotic cardiovascular disease who are on statin therapy and have LDL cholesterol levels of at least 70 mg/dL, the addition of evolocumab reduces the risk of major cardiovascular events—defined as cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization—by 15% over a median follow-up of 2.2 years, with a hazard ratio of 0.85 (95% CI: 0.79–0.92), demonstrating incremental clinical benefit beyond statin monotherapy.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people with heart disease who are already taking cholesterol-lowering statins but still have high LDL, adding a drug called evolocumab can lower their chances of having a heart attack, stroke, or other serious heart problems by about 15% over two years.
See the scientific wording
In patients with atherosclerotic cardiovascular disease who are on statin therapy and have LDL cholesterol levels of at least 70 mg/dL, adding evolocumab reduces the risk of major cardiovascular events—including cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization—by 15% over a median follow-up of 2.2 years, with a hazard ratio of 0.85 (95% CI: 0.79–0.92), providing high-level evidence for incremental benefit beyond statin monotherapy.
What the research says
1 studyStudy: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
The study tested adding evolocumab to statins in heart disease patients and found it reduced heart problems by 15%, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.